NASDAQ:QTNT - Quotient Stock Price, Forecast & News

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient Ltd (NASDAQ:QTNT) issued its quarterly earnings data on Monday, November, 4th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.01. The firm had revenue of $7.85 million for the quarter, compared to analysts' expectations of $6.80 million. View Quotient's Earnings History.

Quotient is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Quotient.

Quotient will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

1 brokerages have issued 12-month target prices for Quotient's stock. Their forecasts range from $13.50 to $13.50. On average, they expect Quotient's stock price to reach $13.50 in the next year. This suggests a possible upside of 71.5% from the stock's current price. View Analyst Price Targets for Quotient.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quotient.

News headlines about QTNT stock have been trending extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Quotient earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Quotient.

Quotient saw a drop in short interest during the month of December. As of December 13th, there was short interest totalling 3,120,000 shares, a drop of 7.4% from the November 28th total of 3,370,000 shares. Based on an average daily trading volume, of 329,100 shares, the short-interest ratio is presently 9.5 days. Currently, 5.3% of the company's stock are sold short. View Quotient's Current Options Chain.

Some companies that are related to Quotient include Myriad Genetics (MYGN), Heska (HSKA), Lantheus (LNTH), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO), GeneNews (GNWSF) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Sorrento Therapeutics (SRNE), Progenics Pharmaceuticals (PGNX), Anavex Life Sciences (AVXL), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), ADMA Biologics (ADMA), Adamis Pharmaceuticals (ADMP), Corbus Pharmaceuticals (CRBP) and Idera Pharmaceuticals (IDRA).

Quotient's stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.09%), FNY Investment Advisers LLC (0.02%) and DAVENPORT & Co LLC (0.02%). Company insiders that own Quotient stock include Brian Mcdonough, Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Prondzynski Heino Von and Roland Boyd. View Institutional Ownership Trends for Quotient.

QTNT stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz and Roland Boyd. View Insider Buying and Selling for Quotient.

QTNT stock was bought by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and DAVENPORT & Co LLC. Company insiders that have bought Quotient stock in the last two years include Brian Mcdonough, Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc and Prondzynski Heino Von. View Insider Buying and Selling for Quotient.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of QTNT stock can currently be purchased for approximately $7.87.

Quotient has a market capitalization of $631.56 million and generates $29.13 million in revenue each year. The company earns $-105,390,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. View Additional Information About Quotient.

The official website for Quotient is http://www.quotientbd.com/.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.